Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.
2012 (English)In: The open ophthalmology journal, ISSN 1874-3641, Vol. 6, 54-8 p.Article in journal (Refereed) Published
Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD.
Place, publisher, year, edition, pages
2012. Vol. 6, 54-8 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-98705DOI: 10.2174/1874364101206010054PubMedID: 22798970OAI: oai:DiVA.org:liu-98705DiVA: diva2:655463